Omeros Corporation (OMER) SEC Filings & Earnings Calls

CHMP negative opinion on narsoplimab MAA in Europe; re-examination ongoing.

“CHMP adopted a negative opinion on our MAA for narsoplimab in TA-TMA.”

European regulatory setback for YARTEMLEA

“In June 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on our marketing authorization application (MAA) for narsoplimab in TA-TMA.” · word for word

High leverage and debt service costs

“Interest expense, net of remeasurement adjustments and other $(7,585) and $(15) for the three months ended June 30, 2026 and 2025, respectively.”

Dependence on YARTEMLEA for revenue

“Our drug product YARTEMLEA (narsoplimab-wuug) is commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients two years of age and older.” · word for word

Stock price volatility from derivative

“Swings in our stock price could significantly affect the valuation of the 2029 Note conversion derivative.” · word for word

Debt repurchase at a premium (approx. 2x principal) may indicate financial strain or opportunistic deleveraging.

“Purchase price $29.0M for $14.5M principal; premium reflects accrued interest and other obligations”

Cash used for repurchases may strain liquidity; replacement debt may have different terms.

“Company may seek to replace cash used with unsecured or limited-collateral debt financing.”

Repurchase price linked to stock trading price; cash outflow may impact liquidity.

“Purchase price subject to adjustment based on trading price of common stock during averaging period.”

Dependence on YARTEMLEA commercial success; pipeline still early-stage.

“YARTEMLEA launch is key; pipeline programs in preclinical/Phase 1.”

Non-cash gains from derivatives inflate net income; adjusted net loss still significant.

“First quarter results include a $73.1 million non-cash gain... Excluding... non-GAAP adjusted net loss... was $17.1 million.” · word for word

Dependence on YARTEMLEA launch success

“Revenue in the current period reflects initial sales of YARTEMLEA to wholesalers in the U.S. As this represents the first period of commercial sales, period-over-period comparisons are limited, and revenue may fluctuate in future periods.” · word for word

Need for additional capital

“We have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future.”

Clinical trial risks for pipeline

“Our clinical trials may fail to show safety or efficacy, show meaningful improvement in efficacy or convenience compared to competitors, produce negative or inconclusive results.”

Commercial execution risk for YARTEMLEA

“Early indicators, including the strong receptivity from transplant centers, the pace of formulary approvals, and the early alignment of payer coverage with the YARTEMLEA label, support our belief that YARTEMLEA could become standard of care in the treatment of TA-TMA.” · word for word

Dependence on Novo Nordisk for zaltenibart milestones

“We are eligible to receive up to $410 million in additional development and regulatory milestone payments, up to $1.3 billion in one-time sales milestone payments, and tiered royalties on annual global net sales of applicable products at rates ranging from high single-digit to high-teens – a total potential value of $2.1 billion plus royalties.” · word for word

Pipeline stage risk for oncology and infectious disease programs

“Investigational New Drug (IND)-enabling studies are underway, with a first-in-human trial slated for late 2027.” · word for word

Dependence on Novo Nordisk partnership for future milestones and royalties.

“Up to $100.0 million in near-term milestone payments and an additional $410.0 million in one-time milestone payments... Up to $1.3 billion in one-time milestone payments” · word for word

Non-cash charge from mark-to-market adjustment on embedded derivatives.

“Includes a $136.0 million non-cash charge associated with the mark-to-market adjustment on the embedded derivatives related to our 2029 Notes and Term Loan” · word for word

Royalty Revenue Dependency

“The availability of royalties from Rayner is dependent on Rayner’s net sales of OMIDRIA and may be of lesser magnitude than anticipated or may not become payable at all” · word for word

NOL Limitation Risk

“if we undergo an ownership change, and our ability to use our pre-change NOL carryforwards and other pre-change tax attributes ... is limited, it would harm our future results of operations” · word for word

Stock Price Volatility

“During the 12-month period ended December 31, 2025, the closing price of our stock ranged from as high as $17.18 per share and as low as $2.97 per share.” · word for word

Preliminary figures subject to adjustment; no revenue or earnings disclosed

“This figure is preliminary and unaudited. It is subject to completion of the Company’s customary financial closing procedures and adjustments.” · word for word

Debt repayment reduces financial risk but reliance on upfront payment for transaction may indicate limited organic cash generation.

“Repayment funded by $240M upfront from transaction, not operating cash flow.”

FDA decision on narsoplimab is delayed; approval not guaranteed

“FDA extended the PDUFA date to December 26, 2025”

Novo Nordisk transaction closing conditions may not be satisfied

“Closing of the transaction is subject to the satisfaction or waiver of certain customary closing conditions” · word for word

Going concern risk

“The conditions described above, including the need to raise additional capital, when evaluated in accordance with the relevant accounting literature, raise substantial doubt with respect to our ability to meet our obligations through one year from the issuance of the Company's condensed consolidated financial statements.” · word for word

Regulatory approval risk

“As with any BLA or MAA, there can be no guarantee that FDA or the EMA will complete their respective reviews within a given timeframe, or that the Company’s BLA or MAA will ultimately be approved.” · word for word

OMIDRIA royalty decline risk

“Net income (loss) from discontinued operations decreased $14.6 million and $25.7 million, respectively, for the three and nine months ended September 30, 2025 due to remeasurement of the OMIDRIA contract royalty asset.” · word for word